All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

AstraZeneca, Amgen's Tezspire receives EU approval targeting TSLP for chronic rhinosinusitis with nasal polyps treatment
Antibody, autoimmune, monoclonal antibody, chronic rhinosinusitis with nasal polyps, TSLP target, combination therapy - Read more

Boehringer Ingelheim's JASCAYD nerandomilast wins China approval for idiopathic pulmonary fibrosis treatment following Ph3 success
Small molecule, respiratory disease, idiopathic pulmonary fibrosis, oral therapy, China approval - Read more

THE GOOD
Business Development & Partnerships

Galera Therapeutics asset acquisition of dismutase mimetics portfolio by Biossil Inc, $105M total deal value
Acquisition, oncology, small molecule, milestone payments - Read more

Novavax transfers Maryland HQ lease to AstraZeneca for $59.8M
Real estate transaction, vaccine, cost optimization, corporate restructuring - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

PROCLIPI study shows survival benefit for advanced cutaneous T-cell lymphoma patients treated with Kyowa Kirin's POTELIGEO
Antibody, cancer, monoclonal antibody, cutaneous T-cell lymphoma, overall survival, CCR4 target - Read more

Sanofi's efdoralprin alfa targeting alpha-1 antitrypsin meets Ph2 goals for alpha-1 antitrypsin deficiency
Protein therapy, rare disease, recombinant protein, alpha-1 antitrypsin deficiency, enzyme inhibitor - Read more

GSK reports positive Ph3 data for low-carbon ventolin salbutamol inhaler targeting asthma and COPD
Small molecule, respiratory, beta-2 agonist, asthma, COPD, inhaler device - Read more

ACM Biolabs reports favorable safety, early efficacy for ACM-CpG TLR9 agonist in Ph1 advanced solid tumors trial
Nanoparticle immunotherapy, cancer, TLR9 agonist, advanced solid tumors, polymersome delivery - Read more

Novartis Cosentyx meets primary endpoints in Ph3 trial for polymyalgia rheumatica, targeting interleukin-17A pathway
Antibody, autoimmune, monoclonal antibody, polymyalgia rheumatica, IL-17 inhibitor - Read more

THE GOOD
Company Launches

LyfeSci Research & Innovation launches patient-centered CRO offering preclinical to clinical trial services
Research services, neurological, clinical trial management, patient-centered approach - Read more

Flagship Pioneering launches Expedition Medicines with $50M to apply AI and covalent chemistry in developing drugs for cancer and immune diseases
AI/ML platform, small molecule, cancer, covalent chemistry, drug discovery - Read more

THE GOOD
Fundraises

Electra raises $183M Series C for rare inflammatory disease drug development
Rare disease, antibody, clinical-stage, autoimmune - Read more

ENA Respiratory raises $22.4M Series B, advancing nasal spray antiviral therapy
Infectious disease, nasal spray, antiviral, clinical-stage - Read more

smartbax raises €4.7M ($5.45M) Pre-Series A, developing antibiotics against multi-drug resistant bacteria
Infectious disease, small molecule, preclinical, antibiotic resistance - Read more

Summit Therapeutics raises $500M private placement for PD-1/VEGF bispecific ivonescimab development
Oncology, bispecific antibody, PD-1/VEGF, clinical-stage - Read more

PleoPharma raises $36M Series B, cannabis addiction and withdrawal treatments
Neurological, addiction, clinical-stage, small molecule - Read more

ENA Respiratory raises $22.4M Series B, developing antiviral host defense enhancers
Infectious disease, antiviral, respiratory, clinical-stage, host defense enhancers - Read more

Starna Therapeutics raises $44M Series B, advancing in vivo CAR-T therapies
In vivo CAR-T, autoimmune, oncology, cell therapy, clinical-stage - Read more [Paywall]

Polaris Partners plans $500M Fund XI raise, longtime biotech investor
Venture capital, biotech investment - Read more

Viridian Therapeutics raises $251M public offering, commercializing treatments for rare diseases
Rare disease, clinical-stage - Read more

Nurix Therapeutics raises $250M public offering, targeted protein degradation medicines development
Oncology, autoimmune, protein degradation, clinical-stage - Read more

VitriVax raises $17.25M Series B, advancing thermostable single-shot vaccine platform technology
Vaccine formulation, platform technology, infectious disease, thermostable technology - Read more

RAPT Therapeutics raises $250M public offering, inflammatory and immunological disease therapies
Clinical-stage, immunology, inflammatory diseases, autoimmune - Read more

THE GOOD
Lawsuits

Regeneron settles Eylea patent dispute with Celltrion, clearing biosimilar launch for December 2026
Monoclonal antibody, ophthalmology, strategic, competitive, patent settlement - Read more

THE GOOD
Mergers & Acquisitions

Hologic goes private in $18.3B acquisition by Blackstone and TPG private equity firms
Diagnostics, women's health, strategic, major transaction - Read more

Alkermes to acquire Avadel Pharmaceuticals for $2.1B to accelerate entry into sleep medicine market
Small molecule, neurological, strategic, major transaction - Read more

Ipsen acquires ImCheck for $1.6B to advance mid-stage leukemia antibody ICT01 into Phase III testing
Monoclonal antibody, oncology, strategic, major transaction - Read more

THE GOOD
Product Launches

Real Chemistry launches AI-powered compliance compass to analyze FDA pharma marketing violation letters
Regulatory, operational, strategic, AI technology - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Arcturus' ARCT-032 mRNA therapy fails Ph2 efficacy endpoint for cystic fibrosis, stock plummets 55%
mRNA therapy, respiratory disease, inhaled therapy, cystic fibrosis, protein synthesis - Read more

Moderna scraps mRNA-1647 cytomegalovirus vaccine program after Ph3 trial shows poor infection prevention efficacy
Vaccine, infectious disease, mRNA vaccine, cytomegalovirus, congenital infection - Read more

THE BAD
Lawsuits

Novartis sues AstraZeneca's Alexion over allegedly false Ultomiris marketing claims against rival Fabhalta drug
Complement inhibitor, rare disease, competitive, regulatory - Read more

10x Genomics sues Illumina over spatial biology and single-cell sequencing patent infringement
Genomics technology, patent litigation, competitive, strategic - Read more

THE BAD
Layoffs

Merck KGaA to close Ireland API plant by 2028, cutting 100 jobs after strategic review
API manufacturing, operational, strategic, cost reduction, investment - Read more

Alector scraps GSK-partnered dementia drug after Phase III failure, cuts 49% of workforce
Monoclonal antibody, neurological, strategic, operational, cost reduction - Read more

THE UGLY
Politics & Policy

Trump prepares Section 301 trade probe targeting foreign drug pricing, potentially imposing new tariffs
Drug pricing policy, regulatory, strategic, financial - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here